Applied DNA Sciences, Inc. (APDN)
USD 0.89
(-2.09%)
USD 0.89
(-2.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.77 Million USD | -6.17% |
| 2022 | 9.35 Million USD | 183.19% |
| 2021 | 3.3 Million USD | -41.34% |
| 2020 | 5.63 Million USD | 27.61% |
| 2019 | 4.41 Million USD | -9.55% |
| 2018 | 4.87 Million USD | 276.52% |
| 2017 | 1.29 Million USD | -75.08% |
| 2016 | 5.2 Million USD | 74.08% |
| 2015 | 2.98 Million USD | -39.94% |
| 2014 | 4.97 Million USD | 32.34% |
| 2013 | 3.75 Million USD | 534.94% |
| 2012 | 592 Thousand USD | -86.84% |
| 2011 | 4.49 Million USD | 49.4% |
| 2010 | 3.01 Million USD | -7.45% |
| 2009 | 3.25 Million USD | -79.52% |
| 2008 | 15.88 Million USD | 10.64% |
| 2007 | 14.35 Million USD | 0.65% |
| 2006 | 14.26 Million USD | 449.45% |
| 2005 | 2.59 Million USD | -45.79% |
| 2004 | 4.78 Million USD | 510.12% |
| 2003 | 784.78 Thousand USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 1283.00 USD | 33.23% |
| 2000 | 963.00 USD | -81.59% |
| 1999 | 5231.00 USD | 43.35% |
| 1998 | 3649.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.35 Million USD | 61.65% |
| 2024 Q1 | 5.78 Million USD | -34.11% |
| 2024 Q3 | 4.45 Million USD | -52.35% |
| 2023 Q3 | 8.59 Million USD | -6.64% |
| 2023 Q4 | 8.77 Million USD | 2.14% |
| 2023 FY | 8.77 Million USD | -6.17% |
| 2023 Q1 | 11.13 Million USD | 19.05% |
| 2023 Q2 | 9.2 Million USD | -17.34% |
| 2022 Q2 | 6.23 Million USD | 107.04% |
| 2022 Q1 | 3.01 Million USD | -8.88% |
| 2022 FY | 9.35 Million USD | 183.19% |
| 2022 Q4 | 9.35 Million USD | 82.54% |
| 2022 Q3 | 5.12 Million USD | -17.76% |
| 2021 Q4 | 3.3 Million USD | 105.71% |
| 2021 Q2 | 2.16 Million USD | -45.35% |
| 2021 Q3 | 1.6 Million USD | -25.7% |
| 2021 Q1 | 3.95 Million USD | -29.77% |
| 2021 FY | 3.3 Million USD | -41.34% |
| 2020 Q2 | 4.05 Million USD | 11.26% |
| 2020 Q3 | 5.19 Million USD | 28.05% |
| 2020 Q1 | 3.64 Million USD | -17.35% |
| 2020 Q4 | 5.63 Million USD | 8.38% |
| 2020 FY | 5.63 Million USD | 27.61% |
| 2019 Q1 | 5.38 Million USD | 10.32% |
| 2019 Q2 | 4.96 Million USD | -7.85% |
| 2019 FY | 4.41 Million USD | -9.55% |
| 2019 Q3 | 4.77 Million USD | -3.77% |
| 2019 Q4 | 4.41 Million USD | -7.55% |
| 2018 Q2 | 2.22 Million USD | 51.41% |
| 2018 FY | 4.87 Million USD | 276.52% |
| 2018 Q4 | 4.87 Million USD | 37.45% |
| 2018 Q3 | 3.54 Million USD | 59.44% |
| 2018 Q1 | 1.47 Million USD | 13.48% |
| 2017 FY | 1.29 Million USD | -75.08% |
| 2017 Q4 | 1.29 Million USD | -46.12% |
| 2017 Q3 | 2.4 Million USD | -38.74% |
| 2017 Q2 | 3.92 Million USD | -14.42% |
| 2017 Q1 | 4.58 Million USD | -11.78% |
| 2016 Q3 | 3.03 Million USD | 13.0% |
| 2016 FY | 5.2 Million USD | 74.08% |
| 2016 Q4 | 5.2 Million USD | 71.46% |
| 2016 Q1 | 2.48 Million USD | -16.69% |
| 2016 Q2 | 2.68 Million USD | 7.84% |
| 2015 Q1 | 1.72 Million USD | -65.4% |
| 2015 FY | 2.98 Million USD | -39.94% |
| 2015 Q4 | 2.98 Million USD | 84.02% |
| 2015 Q3 | 1.62 Million USD | -2.87% |
| 2015 Q2 | 1.67 Million USD | -2.9% |
| 2014 Q2 | 4.1 Million USD | -5.86% |
| 2014 Q3 | 3.45 Million USD | -15.67% |
| 2014 FY | 4.97 Million USD | 32.34% |
| 2014 Q4 | 4.97 Million USD | 43.78% |
| 2014 Q1 | 4.35 Million USD | 15.94% |
| 2013 Q2 | 8.84 Million USD | 6.26% |
| 2013 FY | 3.75 Million USD | 534.94% |
| 2013 Q3 | 1.53 Million USD | -82.66% |
| 2013 Q4 | 3.75 Million USD | 145.12% |
| 2013 Q1 | 8.32 Million USD | 1305.84% |
| 2012 Q3 | 653.91 Thousand USD | 2.46% |
| 2012 Q1 | 3.87 Million USD | -13.86% |
| 2012 FY | 592 Thousand USD | -86.84% |
| 2012 Q4 | 592 Thousand USD | -9.47% |
| 2012 Q2 | 638.23 Thousand USD | -83.53% |
| 2011 FY | 4.49 Million USD | 49.4% |
| 2011 Q4 | 4.49 Million USD | -7.58% |
| 2011 Q3 | 4.86 Million USD | 44.78% |
| 2011 Q2 | 3.36 Million USD | -6.04% |
| 2011 Q1 | 3.57 Million USD | 18.83% |
| 2010 FY | 3.01 Million USD | -7.45% |
| 2010 Q2 | 4.19 Million USD | 4.49% |
| 2010 Q3 | 3.53 Million USD | -15.75% |
| 2010 Q1 | 4.01 Million USD | 23.45% |
| 2010 Q4 | 3.01 Million USD | -14.84% |
| 2009 FY | 3.25 Million USD | -79.52% |
| 2009 Q1 | 13.86 Million USD | -12.72% |
| 2009 Q2 | 1.99 Million USD | -85.61% |
| 2009 Q3 | 2.46 Million USD | 23.8% |
| 2009 Q4 | 3.25 Million USD | 31.74% |
| 2008 Q2 | 16 Million USD | 7.45% |
| 2008 Q1 | 14.89 Million USD | 3.77% |
| 2008 Q3 | 16 Million USD | 0.0% |
| 2008 Q4 | 15.88 Million USD | -0.77% |
| 2008 FY | 15.88 Million USD | 10.64% |
| 2007 FY | 14.35 Million USD | 0.65% |
| 2007 Q3 | 15.19 Million USD | -29.92% |
| 2007 Q4 | 14.35 Million USD | -5.49% |
| 2007 Q1 | 13.42 Million USD | -5.86% |
| 2007 Q2 | 21.67 Million USD | 61.44% |
| 2006 Q3 | 14.09 Million USD | 37.5% |
| 2006 Q4 | 14.26 Million USD | 1.19% |
| 2006 Q1 | 4.15 Million USD | 60.19% |
| 2006 Q2 | 10.25 Million USD | 146.53% |
| 2006 FY | 14.26 Million USD | 449.45% |
| 2005 Q4 | 2.59 Million USD | 68.07% |
| 2005 Q3 | 1.54 Million USD | -32.62% |
| 2005 Q2 | 2.29 Million USD | -61.83% |
| 2005 Q1 | 6 Million USD | 25.4% |
| 2005 FY | 2.59 Million USD | -45.79% |
| 2004 Q1 | 895 Thousand USD | 14.04% |
| 2004 Q3 | 2.12 Million USD | 50.85% |
| 2004 Q4 | 4.78 Million USD | 125.8% |
| 2004 FY | 4.78 Million USD | 510.12% |
| 2004 Q2 | 1.4 Million USD | 57.07% |
| 2003 Q3 | 348.64 Thousand USD | 95.65% |
| 2003 Q1 | 118.75 Thousand USD | 0.0% |
| 2003 Q2 | 178.19 Thousand USD | 50.05% |
| 2003 Q4 | 784.78 Thousand USD | 125.1% |
| 2003 FY | 784.78 Thousand USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 FY | 1283.00 USD | 33.23% |
| 2001 Q4 | - USD | -100.0% |
| 2001 Q1 | 1283.00 USD | 14.15% |
| 2001 Q2 | 1388.00 USD | 8.18% |
| 2001 Q3 | 1493.00 USD | 7.56% |
| 2000 Q4 | 1124.00 USD | 19.07% |
| 2000 Q3 | 944.00 USD | -20.34% |
| 2000 FY | 963.00 USD | -81.59% |
| 2000 Q2 | 1185.00 USD | 23.05% |
| 2000 Q1 | 963.00 USD | 0.0% |
| 1999 FY | 5231.00 USD | 43.35% |
| 1998 FY | 3649.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 78.175% |
| Aspira Women's Health Inc. | 8.62 Million USD | -1.764% |
| Biodesix, Inc. | 94.51 Million USD | 90.711% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -403.988% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -160.796% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -160.796% |
| Bionano Genomics, Inc. | 118.24 Million USD | 92.576% |
| CareDx, Inc | 223.28 Million USD | 96.068% |
| Check-Cap Ltd. | 1.33 Million USD | -560.088% |
| Castle Biosciences, Inc. | 86.54 Million USD | 89.856% |
| DarioHealth Corp. | 38.24 Million USD | 77.045% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.736% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 93.721% |
| Guardant Health, Inc. | 1.62 Billion USD | 99.461% |
| ICON Public Limited Company | 7.74 Billion USD | 99.887% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.506% |
| Illumina, Inc. | 4.36 Billion USD | 99.799% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -56.892% |
| iSpecimen Inc. | 6.07 Million USD | -44.44% |
| Standard BioTools Inc. | 159.86 Million USD | 94.508% |
| MDxHealth SA | 121.92 Million USD | 92.799% |
| 23andMe Holding Co. | 206.64 Million USD | 95.752% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 99.2% |
| Myriad Genetics, Inc. | 312.9 Million USD | 97.194% |
| Mainz Biomed B.V. | 12.15 Million USD | 27.802% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -701.635% |
| NeoGenomics, Inc. | 739.69 Million USD | 98.813% |
| Neogen Corporation | 1.44 Billion USD | 99.39% |
| Inotiv, Inc. | 588.04 Million USD | 98.507% |
| Natera, Inc. | 691.79 Million USD | 98.731% |
| OPKO Health, Inc. | 622.47 Million USD | 98.59% |
| Psychemedics Corporation | 6.59 Million USD | -33.058% |
| Prenetics Global Limited | 44.01 Million USD | 80.053% |
| Prenetics Global Limited | 44.01 Million USD | 80.053% |
| Precipio, Inc. | 3.67 Million USD | -139.084% |
| Personalis, Inc. | 95.65 Million USD | 90.822% |
| RadNet, Inc. | 2.07 Billion USD | 99.577% |
| Sera Prognostics, Inc. | 25.28 Million USD | 65.276% |
| Sotera Health Company | 2.68 Billion USD | 99.673% |
| Neuronetics, Inc. | 81.64 Million USD | 89.247% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 59.496% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 59.496% |
| Trinity Biotech plc | 83.38 Million USD | 89.471% |
| Twist Bioscience Corporation | 152.97 Million USD | 94.261% |
| Exagen Inc. | 34.25 Million USD | 74.367% |